Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Inclusion Criteria

• •Inclusion
• •Patients with histologically confirmed metastatic or unresectable solid tumors for which standard curative measures do not exist or are no longer effective; histology will be limited to those tumors for which temsirolimus or vinorelbine have reported clinical activity: lung, breast, ovary, cervix, prostate, uterus, renal, bladder and neuroendocrine tumors
• •SWOG performance status of 0-2
• •Projected life expectancy of at least 3 months
• •Provision of informed consent prior to any study-related procedures
• •Negative pregnancy test for women of childbearing potential
• •Female patients must not be pregnant due to the potential mutagenicity and teratogenicity of this treatment; a pregnancy test must be administered 7 days prior to administration of therapy to women of childbearing potential; patients must agree to use some form of contraception while on this study at initiation and for the duration of participation in the study; sexually active males must also use a reliable and appropriate method of contraception; post-menopausal women must be amenorrheic for at least 12 months to be considered of nonchildbearing potential
• •Patients must have recovered from acute toxicities from previous surgery, chemotherapy or radiation therapy
• •ANC \>= 1500/mm\^3
• •Platelet count \>= 100,000 cells/mm\^3
• +18 more criteria